Piramal Moves Further Away from Branded Generics with Purchase of Bayer Molecular Imaging Assets
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 4 (Table of Contents)
Published: 30 Apr-2012
DOI: 10.3833/pdr.v2012.i4.1732 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
India’s Piramal Healthcare has agreed to acquire Bayer HealthCare Pharmaceuticals’ molecular imaging portfolio, including the Alzheimer’s disease diagnostic florbetaben, which will be filed for US FDA approval later in 2012 and which will compete with Eli Lilly’s recently approved Amyvid™ (florbetapir F 18) in detecting cerebral beta-amyloid plaques...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS